Research programme: synthetic macrocycles - Ensemble Therapeutics

Drug Profile

Research programme: synthetic macrocycles - Ensemble Therapeutics

Alternative Names: E-36041; IDO checkpoint inhibitors; ubiquitin proteasome inhibitors

Latest Information Update: 19 Jan 2017

Price : $50

At a glance

  • Originator Ensemble Discovery
  • Developer Ensemble Therapeutics; Novartis
  • Class Antineoplastics; Macrocyclic compounds; Small molecules
  • Mechanism of Action Checkpoint kinase inhibitors; Cyclophilin D inhibitors; Cyclophilin inhibitors; Indoleamine-pyrrole 2,3-dioxygenase inhibitors; Inhibitor of apoptosis protein inhibitors; Interleukin 17 receptor antagonists; PCSK9 protein inhibitors; Tryptophan oxygenase inhibitors; Ubiquitin thiolesterase modulators; USP28 protein inhibitors; Usp30 protein inhibitors; USP9X protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Inflammation; Rheumatoid arthritis
  • Research Amyotrophic lateral sclerosis; Cardiovascular disorders; Hepatitis B; Parkinson's disease; Reperfusion injury
  • Discontinued Diabetes mellitus; Pain

Most Recent Events

  • 19 Jan 2017 Discontinued for Diabetes mellitus in USA (PO)
  • 19 Jan 2017 Discontinued for Pain in USA (PO)
  • 19 Jan 2017 Early research in Amyotrophic lateral sclerosis in USA (PO) before January 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top